EORTC Quality of Life Group projects to be presented at ISOQOL 2023

In October, a number of the EORTC Quality of Life Group (QLG) and Quality of Life Department (QLD) members will take part in this year’s conference of the International Society for Quality of Life Research (ISOQOL), presenting latest updates on various projects.

The ISOQOL conference, which this year will be held from 18th to 21st October in Calgary (Canada), brings together a global community of researchers, clinicians, health care professionals, industry professionals, consultants, and patient research partners who all share a common goal: advancing research around health-related quality of life (HRQoL) and patient-reported outcomes (PRO).

Through the presentation of 5 abstracts on this occasion, of which two are oral presentations and one is a symposium, the presenters from the EORTC QLG and QLD will update the conference audience on latest developments on QLG projects, such as the improvement of compliance and standard of data collection and use in trials, the implementation of Health-related Quality of Life research in EORTC clinical trials, or the PRO Item Libraries to assess HRQOL in cancer patients. Please find below an outline of the QLG abstracts to be presented at the ISOQOL conference 2023.

As Dr Jaap Reijneveld, Chair of the EORTC QLG, highlights: “Our presence at this important conference focusing on quality of life enables our group to share the latest updates on the EORTC QLG projects as well as the patient’s experience of cancer treatment. This is crucial to support research aimed not only at increasing cancer survival rate, but also that aimed at improving the quality of life of all cancer patients”.

For more information about the EORTC Quality of Life Group projects, please click here.

Abstract presentations (oral and poster)

Abstract title Authors Presenting author Abstract number/ Presentation details
EORTC QLQ-C30 General Population Normative Data from the UK – Its application in interpretation of national cancer quality of life datasets. Teresa Young, Sandra Nolte, Galina Velikova, Simon Rogers Teresa Young Oral Session 109: Cancer – Clinical Care Applications

Thursday 19th October, 4:05 PM

Achievements in implementation of Health-related Quality of Life research in EORTC clinical trials. Irina Ghislain, Corneel Coens, Ahu Alanya, Abigirl Machingura, Lotte van de Weijst, Jammbe Muroso, Luigi Lim, Madeline Pe Abigirl Machingura Friday Poster Session I
Presentation number: 2041

Friday 20th October, 9:35 AM-10:15 AM

A review of Health-Related Quality of Life (HRQoL) completion rates and reason for low completion in closed EORTC trials. Abigirl Machingura, Lotte van de Weijst, Luigi Lim, Corneel Coens, Irina Ghislain, Ahu Alanya, Madeline Pe Abigirl Machingura Oral Session 306: Cancer Methodology II (306.2)

Saturday 21st October, 4:10 PM-5:40 PM

Improving Completion Rates of Patient-Reported Outcome Measures in Cancer Clinical Trials: What are the recommendations? Lotte van der Weijst, Abigirl Machingura, Ahu Alanya, Emma Lidington, Katarzyna Wac, Lisa Wintner, Lúcia P. C. Senna, Renée Bultijnck, Madeline Pe Lotte van der Weijst Saturday Poster Session II
Presentation number: 3046

Saturday 21st October, 3:25 PM


In addition to the oral and poster presentations, we are very happy to support the Symposium number 8 “State-of-the-Science for Assessing HRQOL in Cancer Patients: PRO Item Libraries, which will provide an overview on how the development of HRQOL instruments in the oncology field evolved over time.

Speakers include:

  • Claire Piccinin, MSc, Quality of Life Department, European Organisation for Research and Treatment of Cancer, Brussels, Belgium
  • Bryce Reeve, PhD, Duke University School of Medicine, Durham, North Carolina, United States
  • Amylou Dueck, PhD, Mayo Clinic, Scottsdale, Arizona, United States

Date: Saturday 21st October, 08:05 AM

Find out more about ISOQOL and the conference programme here.

About the Quality of Life Group

The Quality of Life Group (QLG) strives to improve health-related quality of life (HRQoL) of cancer patients, through dedicated research and the use of HRQoL measures within cancer clinical trials and clinical practice. HRQoL constitutes an important aspect of cancer research and care: it gives a voice to patients, putting their experience at the forefront. The QLG is part of the European Organisation for Research and Treatment of Cancer (EORTC).

For further information, please visit the QLG website:


The European Organisation for Research and Treatment of Cancer (EORTC) is a non-governmental, non-profit organisation, which unites clinical cancer research experts, throughout Europe, to define better treatments for cancer patients to prolong survival and improve quality of life. Spanning from translational to large, prospective, multi-centre, phase III clinical trials that evaluate new therapies and treatment strategies as well as patient quality of life, its activities are coordinated from EORTC Headquarters, a unique international clinical research infrastructure, based in Brussels, Belgium.
For further information, please visit the EORTC website:


Caroline Hance (EORTC QLG)

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023